Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Leases: 2019-2020

Historic Current Leases for Akebia Therapeutics (AKBA) over the last 1 years, with Mar 2020 value amounting to $5.1 million.

  • Akebia Therapeutics' Current Leases fell 83.72% to $5.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $5.1 million, marking a year-over-year decrease of 83.72%. This contributed to the annual value of $5.0 million for FY2019, which is N/A change from last year.
  • Akebia Therapeutics' Current Leases amounted to $5.1 million in Q1 2020, which was up 2.14% from $5.0 million recorded in Q4 2019.
  • Akebia Therapeutics' 5-year Current Leases high stood at $31.3 million for Q1 2019, and its period low was $4.8 million during Q2 2019.
  • Its 2-year average for Current Leases is $10.2 million, with a median of $5.0 million in 2019.
  • Data for Akebia Therapeutics' Current Leases shows a maximum YoY crashed of 83.72% (in 2020) over the last 5 years.
  • Over the past 2 years, Akebia Therapeutics' Current Leases (Quarterly) stood at $5.0 million in 2019, then plummeted by 83.72% to $5.1 million in 2020.
  • Its last three reported values are $5.1 million in Q1 2020, $5.0 million for Q4 2019, and $4.9 million during Q3 2019.